Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

KTTAVery BullishResearch Analysisnews

High materiality9/10

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

May 6, 2025, 9:58 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The strong clinical data and significant stock price increase indicate positive investor sentiment, reflecting a potential turning point for KTTA similar to past biotech rallies following favorable trial results.

AI summary

What happened, with direct paths to the underlying reporting

KTTA shares surged 62.7% in premarket trading. Interim data shows strong target engagement from PAS-004 in trials. Preliminary results indicate pERK levels reduced by up to 91%. One patient with pancreatic cancer showed significant tumor reduction. Safety Review Committee recommends advancing trial to Cohort 6.

KTTA shares surged 62.7% in premarket trading.
Interim data shows strong target engagement from PAS-004 in trials.
Preliminary results indicate pERK levels reduced by up to 91%.
One patient with pancreatic cancer showed significant tumor reduction.
Safety Review Committee recommends advancing trial to Cohort 6.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.